FDA approves Wegovy HD, a higher-dose weight-loss option under a national priority program
The FDA cleared Wegovy HD (7.2 mg) for weight loss and long-term maintenance in adults with obesity or overweight plus a weight-related condition, marking the fourth approval under the Commissioner’s National Priority Voucher program. The higher dose yielded greater average weight loss with a safety profile consistent with prior semaglutide doses, though GI side effects were common and there is a boxed warning for thyroid C-cell tumors; the approval was granted to Novo Nordisk, and a June public hearing on the voucher program is planned.
